Advertisement
Research Article

Randomised Controlled Double-Blind Non-Inferiority Trial of Two Antivenoms for Saw-Scaled or Carpet Viper (Echis ocellatus) Envenoming in Nigeria

  • Isa S. Abubakar,

    Affiliation: Department of Community Medicine, Bayero University of Kano, Kano, Nigeria

    X
  • Saidu B. Abubakar,

    Affiliation: General Hospital Kaltungo, Kaltungo, Gombe State, Nigeria

    X
  • Abdulrazaq G. Habib mail,

    abdulrazaq_habib@yahoo.co.uk

    Affiliation: Department of Medicine, Bayero University Kano, Kano, Nigeria

    X
  • Abdulsalam Nasidi,

    Affiliation: Special Projects Unit, Federal Ministry of Health, Abuja, Nigeria

    X
  • Nandul Durfa,

    Affiliation: Special Projects Unit, Federal Ministry of Health, Abuja, Nigeria

    X
  • Peter O. Yusuf,

    Affiliation: Faculty of Veterinary Medicine, Ahmadu Bello University, Zaria, Nigeria

    X
  • Solomon Larnyang †,

    † Deceased.

    X
  • John Garnvwa,

    Affiliation: Alistair Reid Venom Research Unit, Liverpool School of Tropical Medicine, Liverpool, United Kingdom

    X
  • Elijah Sokomba,

    Affiliation: Department of Pharmacology, University of Jos, Jos, Nigeria

    X
  • Lateef Salako,

    Affiliation: Department of Pharmacology and Therapeutics, University of Ibadan, Ibadan, Nigeria

    X
  • R. David G Theakston,

    Affiliation: Alistair Reid Venom Research Unit, Liverpool School of Tropical Medicine, Liverpool, United Kingdom

    X
  • Ed Juszczak,

    Affiliation: Centre for Statistics in Medicine, University of Oxford, Oxford, United Kingdom

    X
  • Nicola Alder,

    Affiliation: Centre for Statistics in Medicine, University of Oxford, Oxford, United Kingdom

    X
  • David A. Warrell,

    Affiliation: Nuffield Department of Clinical Medicine, John Radcliffe Hospital, University of Oxford, Oxford, United Kingdom

    X
  • for the Nigeria-UK EchiTab Study Group
  • Published: July 27, 2010
  • DOI: 10.1371/journal.pntd.0000767

Viewed info

Cited info

Saved info

Discussed info

Questions or concerns about usage data? Please let us know.